2006
DOI: 10.1038/sj.bmt.1705311
|View full text |Cite
|
Sign up to set email alerts
|

Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients

Abstract: The efficacy and safety of oral valganciclovir was compared to ganciclovir i.v. in pre-emptive treatment of cytomegalovirus (CMV) in T-cell-depleted allogeneic stem cell transplant (allo-SCT) recipients. A therapeutic guideline was developed to allow the safe application of valganciclovir in allo-SCT recipients requiring CMV therapy. In total, 107 consecutive transplant recipients were evaluated. Cytomegalovirus DNA load in plasma was monitored longitudinally; details on antiviral therapy and treatment respons… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

4
30
1
1

Year Published

2007
2007
2014
2014

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 60 publications
(36 citation statements)
references
References 22 publications
4
30
1
1
Order By: Relevance
“…Reasons for these differences may include sample size, the frequency of viral load measurements, and differences in immunologic parameters, such as CMV specific T-cell responses in different populations (19). However, the viral load reductions of 1.06% and 1.07% copies/mL/day for the valganciclovir and ganciclovir groups, respectively, are similar to those achieved in allogenic stem cell transplantation (20). A median initial lag phase of approximately 6 days was commonly observed before a sustained reduction in viral load was achieved, especially in patients with high initial viral loads.…”
Section: Discussionmentioning
confidence: 82%
“…Reasons for these differences may include sample size, the frequency of viral load measurements, and differences in immunologic parameters, such as CMV specific T-cell responses in different populations (19). However, the viral load reductions of 1.06% and 1.07% copies/mL/day for the valganciclovir and ganciclovir groups, respectively, are similar to those achieved in allogenic stem cell transplantation (20). A median initial lag phase of approximately 6 days was commonly observed before a sustained reduction in viral load was achieved, especially in patients with high initial viral loads.…”
Section: Discussionmentioning
confidence: 82%
“…160,161 Oral valganciclovir used as preemptive anti-CMV therapy was shown to have acceptable oral bioavailability and was safe and effective in controlling CMV infection in allogeneic HSCT recipients, including in patients with grades I and II gastrointestinal GVHD. 160,[162][163][164] Thus, valganciclovir is a highly acceptable oral option for preemptive therapy for CMV in the absence of substantial gastrointestinal GVHD.…”
Section: 133mentioning
confidence: 99%
“…These two drugs display similar efficacies in CMV DNA clearance (2), despite the fact that V-GCV leads to higher exposure than does GCV (3). Since intracellular GCV triphosphate is the active form of this compound, the plasma GCV concentration is simply a surrogate of the drug's antiviral activity (1,2).…”
mentioning
confidence: 99%
“…These two drugs display similar efficacies in CMV DNA clearance (2), despite the fact that V-GCV leads to higher exposure than does GCV (3). Since intracellular GCV triphosphate is the active form of this compound, the plasma GCV concentration is simply a surrogate of the drug's antiviral activity (1,2). Monitoring trough plasma GCV levels in AIDS patients receiving oral GCV as maintenance therapy for CMV retinitis was shown to be clinically useful in predicting therapy failure and disease progression (4,5).…”
mentioning
confidence: 99%